Journal article
Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study
V Papademetriou, ES Nylen, M Doumas, J Probstfield, JFE Mann, RE Gilbert, HC Gerstein
American Journal of Medicine | ELSEVIER SCIENCE INC | Published : 2017
Abstract
Background Early stages of chronic kidney disease are associated with an increased cardiovascular risk in patients with established type 2 diabetes and macrovascular disease. The role of early stages of chronic kidney disease on macrovascular outcomes in prediabetes and early type 2 diabetes mellitus is not known. In the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial, the introduction of insulin had no effect on cardiovascular outcomes compared with standard therapy. In this post hoc analysis of ORIGIN, we compared cardiovascular outcomes in subjects without to those with mild (Stages 1-2) or moderate chronic kidney disease (Stage 3). Methods Τwo co-primary composite ..
View full abstractGrants
Awarded by Sanofi
Funding Acknowledgements
The ORIGIN trial was funded by Sanofi; ORIGIN ClinicalTrials.gov number, NCT00069784.